Back to Top Skip to main content

Smallpox

DoD Smallpox Vaccination Program Resource Center

Smallpox Disease and Smallpox Vaccine information paper (includes updated guidance on avoiding contamination while drawing vaccine from the vial)

Questions and Answers about Smallpox and Smallpox Vaccine

SmallpoxSmallpox disease had a mortality rate of approximately 30 percent, and because of a successful vaccination program it was declared globally eradicated in 1980. Naturally occurring smallpox was highly contagious, and was transmitted from an infected person to a susceptible (unvaccinated) person by close contact with respiratory secretions and/or infected skin. When smallpox disease was circulating, the only known reservoir for the virus was humans.

Once infected, a person usually has no symptoms and is not contagious during the incubation period, which ranges from 7-17 days.  Symptoms then begin with high fever, headache, body aches and fatigue. This may last 2-4 days, and then the rash develops. The rash first appears on the oral mucosa, face, and forearms, then spreads to the trunk and legs. A person is most infectious during the first week of the rash and is no longer infectious after all scabs have separated, usually 3-4 weeks after onset.

There is currently one smallpox vaccine licensed in the United States, ACAM2000, and is given in a pre-event setting only to select, designated groups including certain members of the U.S. military. The smallpox vaccine is administered in a single dose by the percutaneous route (scarification) using 15 jabs with a stainless steel bifurcated needle that has been dipped into the reconstituted vaccine. A few days following successful administration of the vaccine, a lesion forms at the vaccination site. This lesion contains vaccinia virus capable of infecting other parts of your body or infecting others who come in contact with the vaccination site directly or anything that contains drainage from the lesion.  For this reason, all smallpox vaccinees are taught, and must practice, proper vaccination site and dressing care. 

Source: Centers for Disease Control and Prevention

You also may be interested in...

Clarifying Guidance for Smallpox and Anthrax Vaccine Immunization Programs

Policy
  • Identification #: N/A
  • Date: 11/12/2015
  • Type: Guidelines
  • Topics: Smallpox | Anthrax

ALCOAST Immunization Update Tdap Smallpox Yellow Fever

Policy

ALCOAST Immunization Update (Tdap, Smallpox, Yellow Fever)

MEDCOM Participation in ACAM2000 Smallpox Vaccine Post-Licensure Safety Surveillance and Research Requirements

Policy
  • Identification #: N/A
  • Date: 10/30/2008
  • Type: Directives
  • Topics: Smallpox

BUMED UPDATE TO CLINICAL POLICY FOR DOD SMALLPOX VACCINATION

Policy

BUMED UPDATE TO CLINICAL POLICY FOR DOD SMALLPOX VACCINATION

  • Identification #: N/A
  • Date: 9/23/2008
  • Type: Directives
  • Topics: Smallpox

Department of Defense Participation in ACAM2000 Smallpox Vaccine Post Marketing Research Requirements

Policy
  • Identification #: N/A
  • Date: 4/15/2008
  • Type: Directives
  • Topics: Smallpox

Update to Clinical Policy for the Department of Defense Smallpox Vaccination Program

Policy
  • Identification #: N/A
  • Date: 4/1/2008
  • Type: Memorandums
  • Topics: Smallpox

Coast Guard Smallpox Vaccine Program

Policy
  • Identification #: N/A
  • Date: 3/3/2008
  • Type: Directives
  • Topics: Smallpox

ALNAV TRANSITION FROM CURRENT DRYVAX SMALLPOX VACCINE TO ACAM2000 SMALLPOX VACCINE

Policy
  • Identification #: N/A
  • Date: 2/27/2008
  • Type: Directives
  • Topics: Smallpox

ALARACT DOD TRANSITION TO ACAM2000 BRAND OF SMALLPOX VACCINE

Policy

ALARACT DOD'S TRANSITION TO ACAM2000 BRAND OF SMALLPOX VACCINE

  • Identification #: N/A
  • Date: 2/14/2008
  • Type: Directives
  • Topics: Smallpox

Transition to ACAM2000 Smallpox Vaccine

Policy
  • Identification #: N/A
  • Date: 1/31/2008
  • Type: Directives
  • Topics: Smallpox

ALCOAST COAST GUARD SMALLPOX VACCINE PROGRAM UPDATE TRANSITION FROM DRYVAX TO ACAM2000

Policy

ALCOAST COAST GUARD SMALLPOX VACCINE PROGRAM UPDATE - TRANSITION FROM DRYVAX TO ACAM2000

  • Identification #: N/A
  • Date: 1/30/2008
  • Type: Directives
  • Topics: Smallpox

Smallpox Immunization Program Safety - Remain Vigilant

Policy
  • Identification #: N/A
  • Date: 3/30/2007
  • Type: Directives
  • Topics: Smallpox

DoD Immunization Program for Biological Warfare Defense AFEB 2005-06

Policy
  • Identification #: N/A
  • Date: 8/22/2005
  • Type: Memorandums
  • Topics: Anthrax | Smallpox

ALMAJCOM SMALLPOX VACCINATIONS FOR CIVILIANS AND CONTRACTORS IN NEWLY DESIGNATED AREAS

Policy

ALMAJCOM SMALLPOX VACCINATIONS FOR CIVILIANS AND CONTRACTORS IN NEWLY DESIGNATED AREAS

  • Identification #: N/A
  • Date: 12/21/2004
  • Type: Directives
  • Topics: Smallpox

MARADMIN EXPANSION OF SVP TO BEGIN IMMUNIZATIONS 60 DAYS PRIOR TO DEPLOYMENT

Policy

MARADMIN EXPANSION OF SMALLPOX IMMUNIZATION PROGRAM AND AUTHORIZATION TO BEGIN IMMUNIZATIONS 60 DAYS PRIOR TO DEPLOYMENT

  • Identification #: N/A
  • Date: 12/21/2004
  • Type: Directives
  • Topics: Smallpox
<< < 1 2 3 > >> 
Showing results 1 - 15 Page 1 of 3

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing: Download a PDF Reader or learn more about PDFs.